Last day of trading in paid subscription shares (Sw. BTA) in Eevia
Eevia Health Plc’s ("Eevia" or “the Company") rights issue has now been registered with the Finnish Trade Register and the shares have been delivered to Euroclear Sweden today and Euroclear Finland yesterday.
For immediate release
Seinäjoki, Finland 15.08.2024
Eevia Health Plc’s ("Eevia" or “the Company") rights issue has now been registered with the Finnish Trade Register and the shares have been delivered to Euroclear Sweden today and Euroclear Finland yesterday. The paid subscription shares (Sw. BTA) will thus be replaced by ordinary shares. The new shares will be booked into the respective custodian/VP account latest on August 22, 2024, and available on August 23.
The last day for trading with BTA on Spotlight Stock Market is August 19, 2024.
Through the rights issue, which ended on June 28, 2024, in Sweden and on July 2, 2024, in Finland Eevia received approximately SEK 17.2 million before issue costs.
As a result of the rights issue the number of shares in Eevia will increase by 28,641,604 shares from 35,713,884 shares to 64,355,488 shares.
ADVISERS
Partner Fondkommission is acting as the financial adviser and issuing agent in Sweden for the rights issue. OP Bank is the issuing agent in Finland.
For further information, please contact:
Stein Ulve, CEO, Eevia Health Plc Joel Westerström, Partner Fondkommission
Email: stein.ulve@eeviahealth.com Email: joel.westerstrom@partnerfk.se
Telephone: +358 400 22 5967 Telephone: +46 735 11 68 53
INFORMATION ABOUT EEVIA HEALTH PLC
Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients in dietary supplements and food brands globally. These global brands utilize the ingredients in their consumer product formulas.
Eevia Health is a manufacturer of 100% organically certified plant extracts. Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia’s other raw materials, such as bilberry, lingonberry, chaga-mushroom, and pine bark, are wild-harvested in a sustainable fashion.
Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. Eevia listed its shares at Spotlight Stock Market in Sweden in June 2021, with the short name EEVIA.
To learn more, please visit www.eeviahealth.com or follow Eevia Health on https://www.linkedin.com/company/eevia-health-oy/?originalSubdomain=fi